55 results about "Mesoderm Cell" patented technology

The present invention provides compositions and methods for the production of differentiated mammalian cells. More particularly, the present invention provides cellular differentiation methods employing culturing the cells on a feeder layer or under feeder-free conditions in cell culture and further contacting the cells with an inhibitor of the PI3-kinase pathway for the generation of differentiated mammalian cells from pluripotent mammalian stem cells. Preferably, the differentiated cell is selected from the group consisting of a mesendodermal cell, a mesodermal cell, and an endodermal cell.

The present invention relates generally to the generation of cells of mesodermal lineage. More particularly, the present invention contemplates a method for the preparation of differentiated or partially differentiated mesodermal cells and their use in tissue repair, regeneration and/or augmentation therapy. The identification and generation of the mesodermal cells further provides a source of transcriptome or proteome data to assess the expression profile of genes associated with the maintenance of mesodermal cells as well as their differentiation, proliferation, expansion and/or renewal potential.

The invention provides an inducing medium for inducing multipotential stem cells to form mesoblastic cells. The inducing medium is prepared from the following components with the corresponding concentrations: 5-15 mM of LiCl, 0.5-2 % of glutamine, 0.5-2 % of non-essential amino acid, 5-15 [mu] M of CHIR99021, 8-15 ng/ml of bFGF, 0.05-0.2 mmol/l of beta mercaptoethanol, 0.2-0.6 [mu] g/ml of hydrocortisone, 4-10 [mu] g/ml of insulin, 80-120 [mu] g/ml of transferrin, 8-12 ng/ml of sodium selenite, 0.05-0.2 mg/ml of penicillin, and 0.05-0.2 mg/ml of streptomycin. For the inducing medium, on the basis of the DMEM/F12 culture medium, some specific cytokines and supplements are added, and thus the probability of inducing the multipotential stem cells to differentiate towards the mesoblastic cells is improved. In addition, the invention provides an inducing method for inducing the multipotential stem cells to form the mesoblastic cells, according to the method, the simple embryoid body for inducing the multipotential stem cells is inoculated to the inducing medium for induced culture, and thus the multipotential stem cells efficiently differentiate to form the mesoblastic cells.

The invention relates to a method to induce primate embryonic stem cells to differentiate into a relatively homogenous population of mesoendoderm cells by treatment with caspase-like inhibitors. Also described is a population of mesoendoderm cells obtained therefrom. The embryonic stem cell derived mesoendoderm cells have the general morphological and cell surface marker characteristics of mesoendoderm cells.

The invention provides a preparation method of epicardial cells from multipotent stem cells. The method comprises the following steps: (1) by activating WNT signal pathways, inducing the multipotent stem cells to be differentiated into mesodermal cells; 2) by inhibiting the WNT signal pathways, converting the mesodermal cells obtained in the step 1) into myocardial precursor cells; 3) by activating retinoic acid signal pathways and the WNT signal pathways, converting the myocardial precursor cells obtained in the step 2) into anterior epicardial cells; and 4) preparing the epicardial cells from the anterior epicardial cells obtained in the step 3). The invention further relates to a method for preparing vascular smooth muscle cells and cardiac fibroblasts from the multipotent stem cells, the epicardial cells, the vascular smooth muscle cells and the cardiac fibroblasts prepared with the method, and application of the epicardial cells, the vascular smooth muscle cells and the cardiac fibroblasts.

The invention discloses a method for realizing efficient differentiation of induced pluripotent stem cells towards mature endothelial cells, belonging to the technical field of cell engineering. The method comprises the following steps: carrying out pretreatment culturing on the induced pluripotent stem cells; carrying out induction to form side plate mesoblastic cells; carrying out inducing to form endothelial progenitor cells tending to the endothelial cells; and carrying out inducing to form the mature endothelial cells. According to the method, various cell inducing factors are matched through increase and decrease, meanwhile, the reasonable upgrading is carried out on the inducing method, thus the directional differentiation of the induced pluripotent stem cells towards the endothelial cells can be efficiently induced, under the condition that a small number of induced pluripotent stem cells are adopted and the purifying operation is not needed, a large number of mature endothelial cells with high purity and complete functions are obtained.

Provided is a method of producing a skeletal muscle progenitor cell using a pluripotent stem cell, particularly an iPS cell, the method comprising the step 1) of culturing a pluripotent stem cell under serum-free conditions, and in the presence of Activin A, to allow the cell to differentiate into a PDGFRα-positive mesodermal cell, and the step 2) of culturing the mesodermal cell under serum-free conditions, and in the presence of a Wnt signal inducer, to allow the cell to differentiate into a skeletal muscle progenitor cell. Also provided are a cell population containing a skeletal muscle progenitor cell as obtained by the method, and a skeletal muscle regeneration promoting agent and therapeutic agent for muscular diseases such as muscular dystrophy, the promoting agent or agent comprising the skeletal muscle progenitor cell as an active ingredient.

This invention relates to a method for producing cardiomyocytes and/or cardiac progenitor cells, comprising culturing an induced pluripotent stem (iPS) cell or embryonic stem (ES) cell, which has been differentiated into a mesoderm cell, in the presence of cyclosporin-A.

The invention provides a method of using multipotent stem cells to prepare epicardial cells, comprising: 1) inducing multipotent stem cells to differentiate into mesodermal cells by activating a WNT signal pathway; 2) converting the mesodermal cells in step 1) into myocardial precursor cells by inhibiting the WNT signal pathway; 3) converting the myocardial precursor cells in step 2) into preliminary epicardial cells by activating a fibroblast growth factor signal pathway and the WNT signal pathway; preparing pericardial cells with the preliminary epicardial cells of step 3). The invention also relates to: a method of using multipotent stem cells to prepare vascular smooth muscle cells and cardiac fibroblasts; epicardial cells, vascular smooth muscle cells and cardiac fibroblasts all of which are prepared through the above method; and their application.

This invention provides pertains to the discovery that that nicotine interrupts molecular signaling between endodermal and mesodermal cells of the lung alveolus. Treatment of the lung with specific molecular agents (e.g., PPAR gamma agonists) can prevent and/or reverse the injury caused by nicotine.

The invention provides a method for inducing and differentiating human embryonic stem cells (hESCs) into mesenchymal stem cells (MSCs). The method mainly relates to three stages, including induction of primitive streak (PS) cells, differentiation to outer mesoderm cells and differentiation of the MSCs. According to the method, a staged differentiation method is adopted, the whole differentiation process can be tracked and subjected to quality control, the cost is low, and operation is easy. An intermediate product of hESCs induced and differentiated into MSCs is obtained and comprises PS cells, outer mesoderm cells and MSCs, more MSCs can be efficiently generated, the multiplication time is shorter, the MSCs can be repeated, and mature MSCs can be obtained in 17 days at the shortest time,wherein the differentiation induction culture media in the first two stages are serum-free culture media with clear components, so that differentiated MSCs are prevented from being polluted by exogenous substances, and the uniformity and clinical applicability of the differentiated MSCs are guaranteed.

The present invention provides a culture method for culturing, in recesses (10), a population including two or more cells including a cell derived from a stem cell and a mesenchymal cell. The cell derived from a stem cell is a cell obtained by differentiating a stem cell in vitro. The cell is a cell of one or more types selected from the group consisting of an endodermal cell, an ectodermal cell, and a mesodermal cell. The population is cultured in the recesses (10) together with a vascular cell or a secretor factor. Each recess (10) includes a space in which cells are movable. When a volume of the space is represented by V mm³ and the number of mesenchymal cells seeded in the space is represented by N, V is 400 or less and N/V is in a range from 35 to 3000.

The invention provides a method for purifying pluripotent vascular progenitor cells from a perinatal tissue. The method comprises the steps of pretreatment and acquisition, wherein in the acquisitionstep, immunomagnetic beads of two different ligands are used for marking and purifying the perinatal tissue cells, the first immunomagnetic beads are used for marking firstly, through positive expression, non-pluripotent vascular progenitor cells are recognized, and impurity cells are removed to obtain a high-concentration cell population containing the pluripotent vascular progenitor cells, thenthe impurity-removed perinatal tissue cells are marked through the second immunomagnetic beads, and recognition is carried out through positive expression to obtain the pluripotent vascular progenitorcells. The pluripotent vascular progenitor cells prepared through the method have phenotypes similar to phenotypes of bone marrow mesenchymal stem cells and perivascular cells at the same time, havethe same mesoderm cell differentiation function as the bone marrow mesenchymal stem cells, further have the functions of differentiating into mature vascular cells and promoting cardiovascular systemrepair and regeneration, and can maintain the cell morphology and the amplification capability.

The present invention relates to a method for producing endothelial cells, in which a step (a) of inducing a mesoblastic cell mass containing endothelial progenitor cells from pluripotent stem cells without forming embryoid bodies and a step (b) of culturing the mesoblastic cell mass containing the endothelial progenitor cells in the presence of RepSox are carried out in this order. According to the present invention, it becomes possible to produce high-quality endothelial cells from pluripotent stem cells with high efficiency. The endothelial cells produced by the method of the present invention are useful, for example, for the production of a myocardial cell sheet, and is expected to be used for the treatment of heart diseases. A myocardial cell sheet can be produced by mixing endothelial cells produced by the method of the present invention with myocardial cells and wall cells and then culturing the mixture.

The present invention relates to a method of generating neural stem cells from mesodermal cells. The invention further provides a cell population which has neural stem cell-like characteristics. The neural stem cells prepared according to the invention are useful in the treatment of neurodegenerative disorders such as Alzheimer's disease and Parkinson's disease.

The invention relates to a method for induced differentiation of human embryonic stem cells into NK cells, and belongs to the technical field of genetic engineering. The method comprises the following steps: resuscitation and passage of human embryonic stem cells, induction to obtain mesoderm cells, induction to obtain CD34 + hematopoietic stem cells, separation and purification of the CD34 + hematopoietic stem cells, induction to obtain NK cells, and multiplication culture. The human embryonic stem cells are human embryonic stem cell lines H9; the recovery and passage of the human embryonic stem cells are as follows: the human embryonic stem cells are recovered and then subjected to passage to the second generation, and when the cell confluence degree is more than 80%, mesoderm cells are obtained through induction; the NK cells are obtained through induced differentiation of human embryonic stem cells, and when the effect-target ratio is 20: 1, the killing rate of HELA tumor cell lines is 94.25%, and the killing rate of LOVO tumor cell lines is 91.24%.

An object of the present application is to provide a method for inducing the differentiation from pluripotent stem cells, particularly iPS cells and ES cells, into ureteric bud cells. Another object of the present application is to provide a system for producing ureteric bud-like tissue from pluripotent stem cells through each stage of differentiations, i.e. anterior primitive streak cells, anterior intermediate mesoderm cells and Wolffian duct cells. Yet another object of the present application is to provide a method for maintaining ureteric bud-like organoids. Another object of the present application is to provide a method for expansion-culturing ureteric bud-like tip tissue.

An improvement to the GiWi protocol for differentiating human pluripotent cells to developmentally mature cardiomyocytes includes a step of activating innate immunity in mesoderm stage cells in the in vitro differentiation culture. When the mesoderm cells, which are precursors to cardiac progenitor cells, are primed by exposure to an activator of innate immunity, a population of cardiomyocytes is generated that is more developmentally mature than is generated in the GiWi protocol without the primed step. Also provided herein are in vitro ventricular conductive microtissues and isolated, in vitro populations of ventricular conduction system-like cells and methods for making the same.